Vaccines may be available for pneumococcal infections, but none of them, including the widely used Prevnar 13, can cover all strains. SutroVax is one of the startups trying to solve that problem, and today raised $64 million to test its approach in humans.
New investors Frazier Healthcare Partners and Pivotal bioVenture Partners led the Series B financing round for Foster City, CA-based SutroVax. Also participating in the round were earlier investors Abingworth, Longitude Capital, Roche Venture Fund, and CTI Life Sciences Fund. In addition to the $60 million Series B investment, SutroVax says the earlier investors are also putting another $4 million into the company.